0001415889-18-001434.txt : 20180926
0001415889-18-001434.hdr.sgml : 20180926
20180926193735
ACCESSION NUMBER: 0001415889-18-001434
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180926
FILED AS OF DATE: 20180926
DATE AS OF CHANGE: 20180926
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: CELGENE CORP /DE/
CENTRAL INDEX KEY: 0000816284
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38662
FILM NUMBER: 181089183
BUSINESS ADDRESS:
STREET 1: 86 MORRIS AVENUE
CITY: SUMMIT
STATE: NJ
ZIP: 07901
BUSINESS PHONE: (908)673-9000
MAIL ADDRESS:
STREET 1: 86 MORRIS AVENUE
CITY: SUMMIT
STATE: NJ
ZIP: 07901
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SUTRO BIOPHARMA INC
CENTRAL INDEX KEY: 0001382101
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 452441988
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 310 UTAH AVE., SUITE 150
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-392-8412
MAIL ADDRESS:
STREET 1: 310 UTAH AVE., SUITE 150
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
3
1
form3-09262018_040920.xml
X0206
3
2018-09-26
0
0001382101
SUTRO BIOPHARMA INC
STRO
0000816284
CELGENE CORP /DE/
86 MORRIS AVENUE
SUMMIT
NJ
07901
false
false
true
false
Series C-2 Redeemable Convertible Preferred Stock
Common Stock
337725
D
Series D Redeemable Convertible Preferred Stock
Common Stock
115227
D
Series D-2 Redeemable Convertible Preferred Stock
Common Stock
758278
D
Series E Redeemable Convertible Preferred Stock
Common Stock
514967
D
Each share of Series C-2 redeemable convertible preferred stock is convertible into 0.0405 share of common stock without payment of further consideration and will automatically convert into 0.0405 share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.
Each share of Series D redeemable convertible preferred stock is convertible into 0.0405 share of common stock without payment of further consideration and will automatically convert into 0.0405 share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.
Each share of Series D-2 redeemable convertible preferred stock is convertible into 0.0419 share of common stock without payment of further consideration and will automatically convert into 0.0419 share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.
Each share of Series E redeemable convertible preferred stock is convertible into 0.0275 share of common stock without payment of further consideration and will automatically convert into 0.0275 share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.
/s/ David Elkins, EVP and Chief Financial Officer
2018-09-26